Amyris Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view top-rated stocks.

Wall Street analysts have given Amyris a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amyris wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Amyris.

Amyris will be holding an earnings conference call on Thursday, August 5th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Amyris, Inc. (NASDAQ:AMRS) released its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.92. The biotechnology company earned $176.90 million during the quarter, compared to the consensus estimate of $73.36 million. The company's quarterly revenue was up 507.9% on a year-over-year basis.
View Amyris' earnings history.

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMRS stock has increased by 386.5% and is now trading at $14.40.
View which stocks have been most impacted by COVID-19.

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $400 million-$400 million, compared to the consensus revenue estimate of $337.46 million.

6 equities research analysts have issued 12-month price objectives for Amyris' stock. Their forecasts range from $3.35 to $35.00. On average, they expect Amyris' stock price to reach $18.23 in the next year. This suggests a possible upside of 26.6% from the stock's current price.
View analysts' price targets for Amyris or view top-rated stocks among Wall Street analysts.

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amyris include Marathon Petroleum (MPC), Phillips 66 (PSX), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), World Fuel Services (INT), Green Plains (GPRE), Clean Energy Fuels (CLNE), CVR Energy (CVI), Delek US (DK), Gevo (GEVO), PBF Energy (PBF), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of AMRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.58%), Davy Global Fund Management Ltd (0.18%), Alliancebernstein L.P. (0.07%), New York State Common Retirement Fund (0.06%), Traynor Capital Management Inc. (0.06%) and Victory Capital Management Inc. (0.06%). Company insiders that own Amyris stock include Frank Kung, John Melo, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, Arizona State Retirement System, and Oppenheimer & Co. Inc.. Company insiders that have sold Amyris company stock in the last year include Frank Kung, and John Melo.
View insider buying and selling activity for Amyris or view top insider-selling stocks.

AMRS stock was acquired by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Davy Global Fund Management Ltd, Alliancebernstein L.P., Victory Capital Management Inc., New York State Common Retirement Fund, Advisor Group Holdings Inc., Golden Green Inc., and Traynor Capital Management Inc.. Company insiders that have bought Amyris stock in the last two years include Frank Kung, and L John Doerr.
View insider buying and selling activity for Amyris or or view top insider-buying stocks.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRS stock can currently be purchased for approximately $14.40.

Amyris has a market capitalization of $4.26 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331,040,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

Amyris employs 595 workers across the globe.

The official website for Amyris is amyris.com.

Amyris is headquartered at 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 450-0761 or via email at [email protected]